R&D News | pharmaphorum

News

Boehringer buys cancer immunotherapy firm T3 for $507m

Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.

News

Genentech, NVIDIA partner on ‘lab-in-a-loop’ AI platform

NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s Genentech subsidiary aimed at accelerating the use of generative artifici

News

MorphoSys shrugs off mixed results for myelofibrosis drug

MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial.

News

MSD reaches $610m deal to buy lysosome biotech Caraway

MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases.

News

GSK says new inhaler will help slash its carbon footprint

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly hal

News

Oxurion files for bankruptcy as DME drug fails

The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint.

Boehringer buys cancer immunotherapy firm T3 for $507m

Genentech, NVIDIA partner on ‘lab-in-a-loop’ AI platform

MorphoSys shrugs off mixed results for myelofibrosis drug

MSD reaches $610m deal to buy lysosome biotech Caraway

GSK says new inhaler will help slash its carbon footprint

Oxurion files for bankruptcy as DME drug fails

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

News

Editor's Picks